F9 and hemophilia A: Recent case reports suggest that emicizumab (Helimbra®) can reduce the risk of bleeding and the requirements for hemostatic therapy in AHA patients as it does in hereditary hemophilia A. Emicizumab (Helimbra®) is a humanized bispecific monoclonal antibody whose mechanism of action mimics the action of FVIII, binds factors IX and X forming the complex, and thereby activates the coagulation cascade without the need for FVIII. Due to its mechanism of action and subcutaneous route of administration, it is associated with a lower risk of complications than bypass agents.